title: Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.
abstract: OBJECTIVE
  Depot medroxyprogesterone acetate (DMPA) reversibly reduces bone mineral density. To estimate the extent to which DMPA might increase fracture risk, we undertook a retrospective cohort study of fractures in DMPA users and users of non-DMPA contraceptives, using the General Practice Research Database.
  
  
  METHODS
  Eligible women were aged younger than 50 years at the qualifying first contraceptive prescription. The DMPA users were classified by DMPA exposure (cumulative and time of last dose) based on prescription records. All incident fractures were included; fracture incidence and risk factors before starting contraceptive use (DMPA or other) also were estimated.
  
  
  RESULTS
  We identified 11,822 fractures in 312,395 women during 1,722,356 person-years of follow-up. Before contraceptive use started, DMPA users had higher fracture risk than nonusers (incidence rate ratio 1.28, 95% confidence interval [CI] 1.07-1.53). After DMPA started, crude fracture incidence was 9.1 per 1,000 person-years for DMPA users and 7.3 for nonusers (crude incidence rate ratio 1.23, 95% CI 1.16-1.30). Fracture risk in DMPA users did not increase after starting DMPA (incidence rate ratio after or before 1.08, 95% CI 0.92-1.26). There was little confounding by age or other factors that could be measured. Fracture incidence was 9.4 per 1,000 person-years in low-exposure DMPA users, and 7.8 per 1,000 in high-exposure DMPA users. The DMPA users had higher fracture risk than nonusers at the start of contraceptive use, with no discernible induction period.
  
  
  CONCLUSIONS
  Although DMPA users experienced more fractures than nonusers, this association may be the result of confounding by a pre-existing higher risk for fractures in women who chose DMPA for contraception.
authors: RTI Health Solutions, Waltham, Massachusetts, and Research Triangle Park, North Carolina; the Michigan Bone & Mineral Clinic, Detroit, Michigan; the Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida; the Division of Adolescent Medicine/Hasbro Children's Hospital and the Department of Pediatrics/Warren Alpert Medical School, Brown University, Providence, Rhode Island; and Pfizer, Collegeville, Pennsylvania, and New York, New York.
authors: Lee L
authors: LL
authors: Lanza
authors: Lisa J
authors: LJ
authors: McQuay
authors: Kenneth J
authors: KJ
authors: Rothman
authors: Henry G
authors: HG
authors: Bone
authors: Andrew M
authors: AM
authors: Kaunitz
authors: Zeev
authors: Z
authors: Harel
authors: Quazi
authors: Q
authors: Ataher
authors: Douglas
authors: D
authors: Ross
authors: Philip L
authors: PL
authors: Arena
authors: Kevin D
authors: KD
authors: Wolter
mesh_terms: D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D012189:Retrospective Studies; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate
references: Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al.. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998–2007.
references: Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use. 4th Edition. Morb Mortal Wkly Rep MMWR 2010;59(RR-4):1–86.
references: Cromer BA, McArdle BJ, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996;129:671–6.
references: Westhoff C. Bone mineral density and DMPA. J Reprod Med 2002;47(Suppl 9):795–9.
references: Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008;77:67–76.
references: Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002;13:581–7.
references: Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006;74:90–9.
references: Harel Z, Johnson CC, Gold MA, Cromer B, Peterson E, Burkman R, et al.. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception 2010;81:281–91.
references: Walker-Orr BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol (Oxf) 1998;49:615–8.
references: Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al.. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18:1947–54.
references: Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier CR, et al.. Validity of the general practice research database. Pharmacotherapy 2003;23:686–9.
references: Van Staa TPA. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000:9:359–66.
references: Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128–36.
references: Savitsky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 1964;36:1627–39.
references: Van Staa TP, Dennison EM, Leufkens HGM, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:517–22.
references: Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929–36.
references: Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005;105:1114–8.
references: Meier CR, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of DMPA and fracture risk. J Clin Endocrin Metab 2010;95:4909–16.
references: Vestergaard P, Rejnmark L, Mosekilde L. The effects of DMPA and intrauterine device use on fracture risk in Danish women. Contraception 2008;78:459–64.
references: Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female army recruits. Osteoporos Int 2001;12:35–42.
references: Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al.. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686–96.
references: Johnson CC, Burkman RT, Gold MA, Brown RT, Harel Z, Bruner A, et al.. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health: study design, population characteristics and baseline bone mineral density. Contraception 2008;77:239–48.